News
“The best outcomes, explains Dr. Modak, “occur when the medication is administered within 3 to 4.5 hours of the onset of ...
Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...
A new study from Shanxi Bethune Hospital revealed that metabolic syndrome (MetS) significantly worsens outcomes in patients ...
Now, a new study from researchers in China suggests that a drug called tirofiban might offer better outcomes than aspirin for ...
The session focused on the evolution of stroke care, particularly ischemic strokes, which make up 87% of all strokes. It ...
Delirium affected 44% of critically ill patients in an Ohio medical center who were hospitalized after a recent stroke, ...
HELSINKI, Finland—Adding IV tirofiban improves functional outcomes among patients undergoing systemic thrombolysis for acute ischemic stroke within 4.5 hours of symptom onset, results from the ...
2mon
Study Finds on MSN3 Health Risks That Increase Odds Of A Disabling StrokeFor example, atrial fibrillation raised the odds of a severe stroke by nearly five times. Regions like South Asia and Africa had the highest rates of severe stroke, highlighting global health ...
Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research suggests.
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...
The US Food and Drug Administration has approved the thrombolytic tenecteplase for the treatment of patients with acute ischemic stroke, manufacturer Genentech announced today. The approval is based ...
Activase ® (alteplase) is indicated for treating patients with acute ischemic stroke (sudden stroke), which is caused by a blood clot in the brain’s blood vessels. Patients can receive Activase only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results